Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 202

1.

Linagliptin for patients aged 70 years or older with type 2 diabetes inadequately controlled with common antidiabetes treatments: a randomised, double-blind, placebo-controlled trial.

Barnett AH, Huisman H, Jones R, von Eynatten M, Patel S, Woerle HJ.

Lancet. 2013 Oct 26;382(9902):1413-23. doi: 10.1016/S0140-6736(13)61500-7. Epub 2013 Aug 13.

PMID:
23948125
[PubMed - indexed for MEDLINE]
2.

2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial.

Gallwitz B, Rosenstock J, Rauch T, Bhattacharya S, Patel S, von Eynatten M, Dugi KA, Woerle HJ.

Lancet. 2012 Aug 4;380(9840):475-83. doi: 10.1016/S0140-6736(12)60691-6. Epub 2012 Jun 28.

PMID:
22748821
[PubMed - indexed for MEDLINE]
3.

Efficacy and tolerability of linagliptin added to a sulfonylurea regimen in patients with inadequately controlled type 2 diabetes mellitus: an 18-week, multicenter, randomized, double-blind, placebo-controlled trial.

Lewin AJ, Arvay L, Liu D, Patel S, von Eynatten M, Woerle HJ.

Clin Ther. 2012 Sep;34(9):1909-19.e15. doi: 10.1016/j.clinthera.2012.07.008. Epub 2012 Aug 29.

PMID:
22939034
[PubMed - indexed for MEDLINE]
4.

Efficacy and safety of linagliptin 2.5 mg twice daily versus 5 mg once daily in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, placebo-controlled trial.

Ross SA, Rafeiro E, Meinicke T, Toorawa R, Weber-Born S, Woerle HJ.

Curr Med Res Opin. 2012 Sep;28(9):1465-74. Epub 2012 Aug 13.

PMID:
22816729
[PubMed - indexed for MEDLINE]
5.

Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study.

Owens DR, Swallow R, Dugi KA, Woerle HJ.

Diabet Med. 2011 Nov;28(11):1352-61. doi: 10.1111/j.1464-5491.2011.03387.x. Erratum in: Diabet Med. 2012 Jan;29(1):158.

PMID:
21781152
[PubMed - indexed for MEDLINE]
6.

Linagliptin monotherapy provides superior glycaemic control versus placebo or voglibose with comparable safety in Japanese patients with type 2 diabetes: a randomized, placebo and active comparator-controlled, double-blind study.

Kawamori R, Inagaki N, Araki E, Watada H, Hayashi N, Horie Y, Sarashina A, Gong Y, von Eynatten M, Woerle HJ, Dugi KA.

Diabetes Obes Metab. 2012 Apr;14(4):348-57. doi: 10.1111/j.1463-1326.2011.01545.x. Epub 2012 Jan 17.

PMID:
22145698
[PubMed - indexed for MEDLINE]
7.

Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor linagliptin: a 4-week multicenter, randomized, double-blind, placebo-controlled phase IIa study in Japanese type 2 diabetes patients.

Horie Y, Kanada S, Watada H, Sarashina A, Taniguchi A, Hayashi N, Graefe-Mody EU, Woerle HJ, Dugi KA.

Clin Ther. 2011 Jul;33(7):973-89. doi: 10.1016/j.clinthera.2011.06.005. Epub 2011 Jul 2.

PMID:
21723606
[PubMed - indexed for MEDLINE]
8.

Effect of linagliptin monotherapy on glycaemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial.

Del Prato S, Barnett AH, Huisman H, Neubacher D, Woerle HJ, Dugi KA.

Diabetes Obes Metab. 2011 Mar;13(3):258-67. doi: 10.1111/j.1463-1326.2010.01350.x.

PMID:
21205122
[PubMed - indexed for MEDLINE]
9.

Efficacy and safety of linagliptin in subjects with type 2 diabetes mellitus and poor glycemic control: pooled analysis of data from three placebo-controlled phase III trials.

Del Prato S, Taskinen MR, Owens DR, von Eynatten M, Emser A, Gong Y, Chiavetta S, Patel S, Woerle HJ.

J Diabetes Complications. 2013 May-Jun;27(3):274-9. doi: 10.1016/j.jdiacomp.2012.11.008. Epub 2013 Feb 9.

PMID:
23403068
[PubMed - indexed for MEDLINE]
10.

Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study.

Gomis R, Espadero RM, Jones R, Woerle HJ, Dugi KA.

Diabetes Obes Metab. 2011 Jul;13(7):653-61. doi: 10.1111/j.1463-1326.2011.01391.x.

PMID:
21410628
[PubMed - indexed for MEDLINE]
11.

Initial combination of linagliptin and metformin improves glycaemic control in type 2 diabetes: a randomized, double-blind, placebo-controlled study.

Haak T, Meinicke T, Jones R, Weber S, von Eynatten M, Woerle HJ.

Diabetes Obes Metab. 2012 Jun;14(6):565-74. doi: 10.1111/j.1463-1326.2012.01590.x. Epub 2012 Mar 21.

PMID:
22356132
[PubMed - indexed for MEDLINE]
12.

The oral DPP-4 inhibitor linagliptin significantly lowers HbA1c after 4 weeks of treatment in patients with type 2 diabetes mellitus.

Forst T, Uhlig-Laske B, Ring A, Ritzhaupt A, Graefe-Mody U, Dugi KA.

Diabetes Obes Metab. 2011 Jun;13(6):542-50. doi: 10.1111/j.1463-1326.2011.01386.x.

PMID:
21352464
[PubMed - indexed for MEDLINE]
13.

Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study.

Taskinen MR, Rosenstock J, Tamminen I, Kubiak R, Patel S, Dugi KA, Woerle HJ.

Diabetes Obes Metab. 2011 Jan;13(1):65-74. doi: 10.1111/j.1463-1326.2010.01326.x.

PMID:
21114605
[PubMed - indexed for MEDLINE]
14.

Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled Type 2 diabetes.

Forst T, Uhlig-Laske B, Ring A, Graefe-Mody U, Friedrich C, Herbach K, Woerle HJ, Dugi KA.

Diabet Med. 2010 Dec;27(12):1409-19. doi: 10.1111/j.1464-5491.2010.03131.x.

PMID:
21059094
[PubMed - indexed for MEDLINE]
15.

Individualised treatment targets for elderly patients with type 2 diabetes using vildagliptin add-on or lone therapy (INTERVAL): a 24 week, randomised, double-blind, placebo-controlled study.

Strain WD, Lukashevich V, Kothny W, Hoellinger MJ, Paldánius PM.

Lancet. 2013 Aug 3;382(9890):409-16. doi: 10.1016/S0140-6736(13)60995-2. Epub 2013 May 23.

PMID:
23706759
[PubMed - indexed for MEDLINE]
16.

Efficacy and safety of linagliptin added to metformin and sulphonylurea in Chinese patients with type 2 diabetes: a sub-analysis of data from a randomised clinical trial.

Zeng Z, Yang JK, Tong N, Yan S, Zhang X, Gong Y, Woerle HJ.

Curr Med Res Opin. 2013 Aug;29(8):921-9. doi: 10.1185/03007995.2013.805123. Epub 2013 Jun 4.

PMID:
23672632
[PubMed - indexed for MEDLINE]
17.

Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial.

Cefalu WT, Leiter LA, Yoon KH, Arias P, Niskanen L, Xie J, Balis DA, Canovatchel W, Meininger G.

Lancet. 2013 Sep 14;382(9896):941-50. doi: 10.1016/S0140-6736(13)60683-2. Epub 2013 Jul 12.

PMID:
23850055
[PubMed - indexed for MEDLINE]
18.

The effect of linagliptin on glycaemic control and tolerability in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.

Singh-Franco D, McLaughlin-Middlekauff J, Elrod S, Harrington C.

Diabetes Obes Metab. 2012 Aug;14(8):694-708. doi: 10.1111/j.1463-1326.2012.01586.x. Epub 2012 Mar 20. Review.

PMID:
22340363
[PubMed - indexed for MEDLINE]
19.

Safety and tolerability of linagliptin: a pooled analysis of data from randomized controlled trials in 3572 patients with type 2 diabetes mellitus.

Schernthaner G, Barnett AH, Emser A, Patel S, Troost J, Woerle HJ, von Eynatten M.

Diabetes Obes Metab. 2012 May;14(5):470-8. doi: 10.1111/j.1463-1326.2012.01565.x. Epub 2012 Feb 16.

PMID:
22268497
[PubMed - indexed for MEDLINE]
20.

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial.

Bailey CJ, Gross JL, Pieters A, Bastien A, List JF.

Lancet. 2010 Jun 26;375(9733):2223-33. doi: 10.1016/S0140-6736(10)60407-2.

PMID:
20609968
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk